L3VLUP
ProSign in

XENE · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

XENEVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • XENE
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterXENEVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 20211 holders, $14m31 holders, $15.4bn
Q2 20211 holders, $17m30 holders, $12.7bn
Q3 20212 holders, $20m35 holders, $10.1bn
Q4 20214 holders, $205m28 holders, $12.4bn
Q1 20226 holders, $215m23 holders, $16.1bn
Q2 20227 holders, $230m25 holders, $18.1bn
Q3 20227 holders, $330m22 holders, $18.4bn
Q4 20228 holders, $303m28 holders, $18.4bn
Q1 20239 holders, $259m26 holders, $21.4bn
Q2 20235 holders, $222m27 holders, $24.7bn
Q3 20237 holders, $220m33 holders, $24.3bn
Q4 202311 holders, $590m32 holders, $28.6bn
Q1 20246 holders, $396m31 holders, $29.8bn
Q2 20247 holders, $383m29 holders, $33.4bn
Q3 20247 holders, $428m27 holders, $33.5bn
Q4 20246 holders, $400m26 holders, $28.5bn
Q1 20255 holders, $343m21 holders, $35.4bn
Q2 20255 holders, $224m21 holders, $32.3bn
Q3 20255 holders, $415m22 holders, $25.9bn
Q4 20256 holders, $501m26 holders, $31.8bn
Q1 20268 holders, $1.3bn25 holders, $31.8bn
Q2 20269 holders, $1.2bn26 holders, $34.6bn
XENE

Xenon Pharmaceuticals Inc

Holders
7
Reported value
$383m
Buyers
3
Sellers
2

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
29
Reported value
$33.4bn
Buyers
12
Sellers
18

Breadth -6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 32 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only XENE (3)

ExodusPoint Capital Management LP, Moore Capital Management LP, Point72 Asset Management LP

Only VRTX (25)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →